Here are relevant reports on : craft-beer-market-research-report-2020
-
New Report Test
Test
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
360Product report
360Product
- Published: March 2026
- Price: $ 8150
- TOC Available:
-
Cardiac Tissue Engineering Market by Material (Scaffold, Stem cells), Product (Heart Valve, Vascular Grafts), Applications (MI,Congenital Heart Disease), End-User (Hospitals & Clinics, Academics & Research Institutes) - Global Forecast to 2029
The global cardiac tissue engineering market, valued at US$546.8 million in 2023, stood at US$621.2 million in 2024 and is projected to advance at a resilient CAGR of 16.5% from 2024 to 2029, culminating in a forecasted valuation of US$1,333.6 million by the end of the period. This growth is driven by increased demand for regenerative medicine, advancements in 3D bioprinting, and rising cardiovascular disease prevalence.
- Published: September 2024
- Price: $ 4950
- TOC Available:
-
Immunofluorescence Assay Market by Product (Reagent, Instruments, Antibodies, Kits, Consumables & Accessories), Type (Direct, Indirect), Disease (Infectious Disease, Other Diseases), End User (Contract Research Organizations) – Global Forecast to 2026
The immunofluorescence assays market is expected to grow from USD 2.6 billion in 2021 to USD 83.5 billion by 2026, at a compound annual growth rate (CAGR) of 6.0% during the forecast period.Thermo Fisher Scientific Inc (US), Abcam PLC (UK), Bio-Rad Laboratories, Inc (US), PerkinElmer Inc. (US), Merck KGaA (Germany), Werfen Company (Spain), Cell Signaling Technology, Inc. (US), MEDIPAN GmbH (Germany)
- Published: February 2021
- Price: $ 4950
- TOC Available:
-
Ligase Enzymes Market by Type (DNA, RNA), Source (Viral, Bacterial, Eukaryotic), Grade (RUO, GMP, Diagnostic), Molecular Biology Workflow (Cloning, Sequencing, Synthetic Biology), Application (Research, Diagnostic, Therapeutic) - Global Forecast 2030
The global ligase enzymes market, valued at US$0.25 billion in 2024, stood at US$0.26 billion in 2025 and is projected to advance at a resilient CAGR of 6.8% from 2025 to 2030, culminating in a forecasted valuation of US$0.36 billion by the end of the period. The ligase enzymes market is growing due to the rising demand for molecular diagnostics, the increasing adoption of next-generation sequencing (NGS), expanding applications in synthetic biology, and continuous advancements in enzyme engineering.
- Published: September 2025
- Price: $ 4950
- TOC Available:
-
Western Blotting Market by Product, (Consumables (Antibody), Instrument (Electrophoresis, Blotting System, Imager (Fluorescent))), Application (Biomedical, Clinical Diagnostics), End User (Research Institute, Hospital, Biopharma) & Region - Global Forecast to 2026
The global western blotting market growth is primed to transition from $1.0 billion in 2021 to $1.4 billion by 2026, showcasing a strong CAGR of 6.7%. Technological advancements, increasing government funding in the field of biomedical research, growing demand for personalized medicine, and the rising prevalence of HIV are the key factors driving the market growth.
- Published: November 2021
- Price: $ 4950
- TOC Available:
-
Top 10 Cellular Analysis Market by Technology (Imaging, PCR, Flow Cytometry, High-content Screening, Blotting, Spectrophotometry), Application (Stem Cell, Cancer, Tissue Engineering) & End User (Biotechnology, Research) - Global Forecast to 2021
The top 10 cellular analysis market is expected to reach USD 41.34 Billion by 2021 from USD 28.66 Billion in 2016, at a CAGR of 7.6% during the forecast period. Cellular analysis is used for cell identification, cell interaction, cell viability, cell proliferation, cell structure study, cell signaling/cell transduction, target identification & validation, cell counting, and quality control. Currently, cellular analysis technologies are used in various phases of the drug discovery process, cancer diagnosis (oncology), blood cell analysis, toxicity testing, personalized medicine, pathogen testing, and other applications.
- Published: January 2017
- Price: $ 4950
- TOC Available:
-
Single Cell Sequencing Market by Product (Reagents & Kits, Platforms, Software), Workflow (Presequencing), Service (Sample Preparation, Bioinformatics), Sequencing (scRNA, scDNA), Application (Research, Diagnostic), End User - Global Forecast to 2030
The global Single Cell Sequencing market, valued at US$1.89 billion in 2024, stood at US$1.95 billion in 2025 and is projected to advance at a resilient CAGR of 12.2% from 2025 to 2030, culminating in a forecasted valuation of US$3.46 billion by the end of the period. This growth is driven by advancements in single-cell workflow, including more efficient cell isolation methods, improved library preparation kits, and high-throughput, cost-effective sequencing platforms.
- Published: July 2025
- Price: $ 4950
- TOC Available:
-
Precision Medicine Software Market by Delivery Mode (On-Premise & Cloud-Based), End User (Healthcare Providers, Research Centers & Government Institutes, Pharmaceutical & Biotechnology Companies), Application, and Region - Global Forecast to 2024
The precision medicine software market is projected to reach USD 2.0 billion by 2024, at a CAGR of 11.5%. Factors such as the rising government funding in precision medicine initiatives, partnerships among pharmaceutical and software companies, the entry of new players & VC funding, and growth in the number of cancer patients are driving the growth of the precision medicine software market. However, the high cost of deployment, issues related to the secure storage of large volumes of sequenced data, lack of reimbursement for precision medicine-based treatments, and the dearth of skilled IT professionals in healthcare are expected to restrain market growth to a certain extent in the coming years. Syapse, Inc. (US), 2bPrecise LLC (Israel), Foundation Medicine, Inc. (US), Fabric Genomics (US), SOPHiA GENETICS SA (Switzerland), PierianDx, Inc. (US), N-of-One, Inc. (US), Human Longevity, Inc. (US), Translational Software, Inc. (US), Sunquest Information Systems Inc. (US), Gene42, Inc. (Canada), LifeOmic Health, LLC (US), NantHealth, Inc. (US), Tempus Labs, Inc. (US), Flatiron Health, Inc. (US), IBM Watson Group (US), and Koninklijke Philips N.V. (Netherlands)
- Published: March 2019
- Price: $ 4950
- TOC Available:
-
Minimal Residual Disease Market by Product (Kits, Instruments), Technology (PCR, NGS), Application (Leukemia, Lymphoma, Multiple Myeloma, Solid Tumors), End User (Hospitals, Diagnostic Labs, Research Institutes), & Region - Global Forecast to 2029
The global minimal residual disease testing market, valued at US$1.27 billion in 2023, stood at US$1.43 billion in 2024 and is projected to advance at a resilient CAGR of 12.2% from 2024 to 2029, culminating in a forecasted valuation of US$2.55 billion by the end of the period. The market is driven by the growing prevalence of cancer globally and increasing funding from international organizations and governments for cancer prevention programs.
- Published: February 2025
- Price: $ 4950
- TOC Available:
Records 41 to 50 of 50